Lu AF82422 is often a mAb proven as Risk-free and properly tolerated within a phase I trial in healthful topics and individuals with PD (NCT03611569). A phase II review investigating the protection and efficacy in https://rebeccadhld772093.bloguetechno.com/detailed-notes-on-parkinson-s-vs-multiple-system-atrophy-65608641